- February 2020 |
- Healthcare & Pharmaceutical / Pharmaceuticals
Global Drugs for Vulvovaginal Candidiasis (VVC) Market Size, By Formulation Type (Topical (Cream, Lotion, Gel, Ointment, Aerosol, Foam, Powder, Solution etc.), Pessary (Suppositories, Kit), and Oral (Tablet, Capsule, Powder for Suspension etc.)), By Drug Types (Miconazole, Clotrimazole, Fluconazole, Econazole, and Others (Itraconazole, Nystatin, Tioconazole, amphotericin B Etc.)), and By End User (Hospital, Clinic, and Pharmacy), and By Region (North America, Europe, Asia Pacific, Middle East & Africa and Latin America); Trend Analysis, Competitive Market Share & Forecast, 2016-26
Global Drugs for Vulvovaginal Candidiasis (VVC) Market Forecast and Trends
The global Drugs for Vulvovaginal Candidiasis (VVC) market is anticipated to grow nearly at a CAGR of 3.76% to reach US$ 1,006 million by 2026. The key drivers of growth are projected to be the increase in the number of patients affected by candidiasis infection, and high acceptance due to innovative vulvovaginal candidiasis drugs are predicted to be major drivers of market growth over the forecast period. Increasing consumer awareness of candidiasis and increasing number of treatment options are major drivers of candidiasis market...